Eurofins-Cerep Valuation
Is ALECR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALECR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALECR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALECR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALECR?
Key metric: As ALECR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ALECR's PE Ratio? | |
|---|---|
| PE Ratio | 12.7x |
| Earnings | €7.64m |
| Market Cap | €97.35m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 11.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does ALECR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 36.1x | ||
PCA PCAS | 12.5x | n/a | €109.9m |
ERF Eurofins Scientific | 26.5x | 18.3% | €8.6b |
OSE OSE Immunotherapeutics | 4.2x | -72.5% | €191.2m |
DIM Sartorius Stedim Biotech | 101.4x | 31.9% | €16.3b |
ALECR Eurofins-Cerep | 12.7x | n/a | €97.3m |
Price-To-Earnings vs Peers: ALECR is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (36.1x).
Price to Earnings Ratio vs Industry
How does ALECR's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: ALECR is good value based on its Price-To-Earnings Ratio (12.7x) compared to the European Life Sciences industry average (37.1x).
Price to Earnings Ratio vs Fair Ratio
What is ALECR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 12.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALECR's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sanofi
€114.5b
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
SAN
€91.47
7D
-4.4%
1Y
7.1%
Eurofins Scientific
€8.6b
Provides various analytical testing and laboratory services worldwide.
ERF
€45.57
7D
-1.3%
1Y
-11.3%
Theranexus Société Anonyme
€3.9m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€0.50
7D
1.2%
1Y
-58.0%